204 related articles for article (PubMed ID: 20429865)
21. Evolution of the primate trypanolytic factor APOL1.
Thomson R; Genovese G; Canon C; Kovacsics D; Higgins MK; Carrington M; Winkler CA; Kopp J; Rotimi C; Adeyemo A; Doumatey A; Ayodo G; Alper SL; Pollak MR; Friedman DJ; Raper J
Proc Natl Acad Sci U S A; 2014 May; 111(20):E2130-9. PubMed ID: 24808134
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
[TBL] [Abstract][Full Text] [Related]
23. The trypanosome lytic factor of human serum and the molecular basis of sleeping sickness.
Vanhamme L; Pays E
Int J Parasitol; 2004 Jul; 34(8):887-98. PubMed ID: 15217727
[TBL] [Abstract][Full Text] [Related]
24. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
Gehrig S; Efferth T
Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
[TBL] [Abstract][Full Text] [Related]
25. Increased trypanolytic activity in sera of sleeping sickness patients after chemotherapy.
Fischer A; Simarro PP; Franco JR; Becher H; Steverding D
Trop Med Int Health; 2001 Dec; 6(12):1070-4. PubMed ID: 11737844
[TBL] [Abstract][Full Text] [Related]
26. APOLs with low pH dependence can kill all African trypanosomes.
Fontaine F; Lecordier L; Vanwalleghem G; Uzureau P; Van Reet N; Fontaine M; Tebabi P; Vanhollebeke B; Büscher P; Pérez-Morga D; Pays E
Nat Microbiol; 2017 Nov; 2(11):1500-1506. PubMed ID: 28924146
[TBL] [Abstract][Full Text] [Related]
27. The TgsGP gene is essential for resistance to human serum in Trypanosoma brucei gambiense.
Capewell P; Clucas C; DeJesus E; Kieft R; Hajduk S; Veitch N; Steketee PC; Cooper A; Weir W; MacLeod A
PLoS Pathog; 2013; 9(10):e1003686. PubMed ID: 24098129
[TBL] [Abstract][Full Text] [Related]
28. Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48.
Martínez-García M; Bart JM; Campos-Salinas J; Valdivia E; Martínez-Bueno M; González-Rey E; Navarro M; Maqueda M; Cebrián R; Pérez-Victoria JM
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):203-212. PubMed ID: 29649664
[TBL] [Abstract][Full Text] [Related]
29. Veterinary link to drug resistance in human African trypanosomiasis?
Barrett MP
Lancet; 2001 Aug; 358(9282):603-4. PubMed ID: 11530144
[No Abstract] [Full Text] [Related]
30. Trypanosome alternative oxidase, a potential therapeutic target for sleeping sickness, is conserved among Trypanosoma brucei subspecies.
Nakamura K; Fujioka S; Fukumoto S; Inoue N; Sakamoto K; Hirata H; Kido Y; Yabu Y; Suzuki T; Watanabe Y; Saimoto H; Akiyama H; Kita K
Parasitol Int; 2010 Dec; 59(4):560-4. PubMed ID: 20688188
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting.
Lüscher A; de Koning HP; Mäser P
Curr Pharm Des; 2007; 13(6):555-67. PubMed ID: 17346174
[TBL] [Abstract][Full Text] [Related]
32. Activity of human trypanosome lytic factor in mice.
Barker C; Barbour KW; Berger FG; Hajduk SL
Mol Biochem Parasitol; 2001 Oct; 117(2):129-36. PubMed ID: 11606222
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the cytolytic effects in vitro on Trypanosoma brucei brucei of plasma, high density lipoproteins, and apolipoprotein A-I from hosts both susceptible (cattle and sheep) and resistant (human and baboon) to infection.
Gillett MP; Owen JS
J Lipid Res; 1992 Apr; 33(4):513-23. PubMed ID: 1527475
[TBL] [Abstract][Full Text] [Related]
34. In vitro generation of human high-density-lipoprotein-resistant Trypanosoma brucei brucei.
Faulkner SD; Oli MW; Kieft R; Cotlin L; Widener J; Shiflett A; Cipriano MJ; Pacocha SE; Birkeland SR; Hajduk SL; McArthur AG
Eukaryot Cell; 2006 Aug; 5(8):1276-86. PubMed ID: 16896212
[TBL] [Abstract][Full Text] [Related]
35. Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter.
Gilbert IH
Parasitology; 2014 Jan; 141(1):28-36. PubMed ID: 23931634
[TBL] [Abstract][Full Text] [Related]
36.
Cooper A; Ilboudo H; Alibu VP; Ravel S; Enyaru J; Weir W; Noyes H; Capewell P; Camara M; Milet J; Jamonneau V; Camara O; Matovu E; Bucheton B; MacLeod A
Elife; 2017 May; 6():. PubMed ID: 28537557
[TBL] [Abstract][Full Text] [Related]
37. Genetic and immunological basis of human African trypanosomiasis.
Pays E; Nolan DP
Curr Opin Immunol; 2021 Oct; 72():13-20. PubMed ID: 33721725
[TBL] [Abstract][Full Text] [Related]
38. The trypanolytic factor-mechanism, impacts and applications.
Wheeler RJ
Trends Parasitol; 2010 Sep; 26(9):457-64. PubMed ID: 20646962
[TBL] [Abstract][Full Text] [Related]
39. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.
Sharma AK; Friedman DJ; Pollak MR; Alper SL
FEBS J; 2016 May; 283(10):1846-62. PubMed ID: 26945671
[TBL] [Abstract][Full Text] [Related]
40. [Human resistance to African trypanosoma infections].
Perez-Morga D
Bull Mem Acad R Med Belg; 2007; 162(7-9):381-6; discussion 386. PubMed ID: 18429487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
